What is the evidence for using concurrent chemoradiotherapy with temozolomide and adjuvant temozolomide in patients with recurrent low‑grade glioma that have MGMT promoter methylation and CpG island methylation of exons 1‑4?

Treatment Recommendation for MGMT-Methylated Recurrent Low-Grade Glioma

For patients with recurrent low-grade glioma harboring MGMT promoter methylation (including CpG sites 1-4), concurrent chemoradiotherapy with temozolomide followed by adjuvant temozolomide is strongly supported, though the evidence base is primarily extrapolated from newly diagnosed high-grade glioma data and limited phase II studies in low-grade disease.

Critical Evidence Gap

The 2022 ASCO-SNO guidelines explicitly state: "No recommendation for or against any therapeutic strategy can be made for treatment of recurrent glioblastoma" and strongly recommend clinical trial enrollment for recurrent disease 1. This absence of evidence-based recommendations for recurrent high-grade glioma extends even more profoundly to recurrent low-grade glioma, where prospective randomized data are essentially nonexistent.

Evidence Supporting Temozolomide in This Context

Low-Grade Glioma-Specific Data

The strongest direct evidence comes from phase II studies in low-grade gliomas:

• MGMT methylation predicts response: In 68 low-grade gliomas treated with neoadjuvant temozolomide, methylated MGMT was detected in 92.6% and was a favorable predictor of progression-free survival compared to unmethylated tumors (p < 0.0001) 2

• Quantitative methylation matters: A study of 22 WHO grade II gliomas treated with temozolomide showed that volumetric MRI response and time to progression correlated with the level of MGMT promoter methylation, suggesting quantitative methylation-specific PCR predicts radiological response 3

Extrapolation from Newly Diagnosed Disease

For newly diagnosed astrocytoma, IDH-mutant, 1p19q non-codeleted, CNS WHO grade 3 (the closest analog to progressed low-grade glioma), the ASCO-SNO guidelines provide a strong recommendation: "People with astrocytoma, IDH-mutant, 1p19q non-codeleted CNS WHO grade 3 should be offered RT with adjuvant TMZ" 1

The FDA label for temozolomide demonstrates efficacy in refractory anaplastic astrocytoma at first relapse, with an overall response rate of 22% and median progression-free survival of 4.4 months 4. While this represents recurrent disease, it was grade 3 (not grade 2) at recurrence.

Treatment Algorithm for MGMT-Methylated Recurrent Low-Grade Glioma

Step 1: Confirm Molecular Status

• Verify MGMT promoter methylation status (ideally quantitative, with methylation ≥11% considered methylated per recent pyrosequencing data 5)
• Confirm IDH mutation status and 1p/19q codeletion status
• Document WHO grade at recurrence (grade 2 vs. transformation to grade 3/4)

Step 2: Treatment Selection Based on Grade at Recurrence

If recurrence shows grade 3 transformation:

• Proceed with concurrent chemoradiotherapy: Radiotherapy (50-60 Gy in 1.8-2 Gy fractions) with concurrent temozolomide 75 mg/m² daily throughout radiotherapy 6
• Follow with adjuvant temozolomide: 150-200 mg/m² days 1-5 of every 28-day cycle for 6 cycles 1
• This approach is directly supported by guidelines for grade 3 IDH-mutant astrocytoma 1

If recurrence remains grade 2:

• Consider temozolomide monotherapy (150-200 mg/m² days 1-5 every 28 days) given the strong predictive value of MGMT methylation in this population 2, 3
• Radiotherapy alone or combined chemoradiotherapy are reasonable alternatives, though data are limited
• Clinical trial enrollment should be prioritized 1

Step 3: Duration and Monitoring

• Continue treatment for 6 cycles unless progression or toxicity occurs 1
• No evidence supports extending beyond 6 cycles 1
• Monitor for pseudoprogression during first 3 months after chemoradiotherapy 1

Critical Caveats

MGMT methylation interpretation varies by context: In IDH-mutant astrocytomas, MGMT methylation may partly reflect IDH-associated global hypermethylation and has limited independent clinical value compared to IDH-wildtype glioblastoma 7. The predictive value is strongest when treatment with alkylating agents is being considered.

Technical factors matter: Assay platform, CpG-site selection, cutoff definition, and tumor heterogeneity all affect interpretation 7. Borderline results (8-11% methylation) represent a gray zone 5.

Resistance development: Loss of MGMT promoter methylation is a major cause of chemoresistance, and the entire epigenome changes with temozolomide exposure 8. This is particularly relevant in the recurrent setting.

Age and performance status: The standard concurrent chemoradiotherapy regimen was validated in patients aged 18-70 years with KPS ≥70 1. Modifications may be needed outside these parameters.

Practical Implementation

The EANO guidelines specify that for IDH-mutant gliomas, the benefit from temozolomide is largely limited to patients with MGMT promoter-methylated tumors 6. Given your patient has both MGMT methylation and CpG island methylation of exons 1-4, this represents a favorable molecular profile for alkylating chemotherapy response.

The most defensible approach: Treat as you would a newly diagnosed grade 3 IDH-mutant astrocytoma with concurrent chemoradiotherapy and adjuvant temozolomide, recognizing this extrapolates from higher-grade disease but is supported by the biological rationale of MGMT methylation predicting temozolomide sensitivity 9, 2, 3.